A first in human clinical trial of TVT-004
Latest Information Update: 17 Feb 2022
At a glance
- Drugs TVT-004 (Primary)
- Indications Neuropathic pain; Pain
- Focus Adverse reactions; First in man
- Sponsors Travecta Therapeutics
- 15 Feb 2022 According to a Travecta Therapeutics media release, this study is expected to begin in Q4 2022.
- 10 Jun 2021 According to a Travecta Therapeutics media release, company is expecting first volunteer will be dosed during the first quarter of 2022.
- 19 Nov 2020 New trial record